Joe (little) Gordon’s BHC trading history for Q1 2020:
1/7/20
-2,118 shares @ $29.42 = $63,311.56
2/19/20
+5,242 SharesJ
+28,178 Shares @ $0
-11,703 Shares @ $26.46 = $309,661.38
J = Explanation of Responses:
(1)
Reflects common shares, no par value ("Common Shares") of Bausch Health Companies Inc. (the "Company") issued to the reporting person in connection with the vesting of performance-based Restricted Share Units ("PSUs") granted to the reporting person on January 6, 2017.
(2)
On January 6, 2017, the reporting person was granted PSUs that were distributed on February 19, 2020 following certification of the achievement of certain performance metrics.
(3)
Each PSU converts into Common Shares on a one-for-one basis.
(4)
This number represents Common Shares withheld to satisfy the tax withholding obligations due upon vesting of PSUs.
(5)
This PSU award was previously reported on a Form 3 filed on August 10, 2018 with the target award amount of 5,461 shares. Any portion of the award not vested on February 19, 2020 was cancelled as of that date.
2/26/20
+13,506 @ $0
2/28/20
-2,499 shares @ $24.44 = $61,075.56
3/9/20
-2,239 Shares @ $20.96 = $46,929.44
Fat Joe’s protégé, Joe (little) Gordon, sold 18,559 shares in Q1 2020 averaging approximately $25.92/share totaling $480,977.94. Not bad, but nothing compared to Fat Joe!
Does little Joe know who the Bear Jew is?
“We are pleased with the findings of the court, which demonstrates the integrity of our PreserVision AREDS and AREDS 2 Formula eye vitamins to meet the needs of eye care professionals and their patients,” Joseph Gordon, senior vice president and general manager, Bausch + Lomb Consumer Healthcare, said in the news release. “As the leader in ocular nutrition, Bausch + Lomb is committed to providing the most current, science-based eye vitamin formulations. Therefore, when these or any of our products are infringed, we will vigorously defend our intellectual property and innovations to ensure our customers can continue to rely on products that are based on a robust body of scientific and clinical research.”
Little Joe is not, nor is B+L, the leader in anything other than being a weak and deceptive fraud.
1/7/20
-2,118 shares @ $29.42 = $63,311.56
2/19/20
+5,242 SharesJ
+28,178 Shares @ $0
-11,703 Shares @ $26.46 = $309,661.38
J = Explanation of Responses:
(1)
Reflects common shares, no par value ("Common Shares") of Bausch Health Companies Inc. (the "Company") issued to the reporting person in connection with the vesting of performance-based Restricted Share Units ("PSUs") granted to the reporting person on January 6, 2017.
(2)
On January 6, 2017, the reporting person was granted PSUs that were distributed on February 19, 2020 following certification of the achievement of certain performance metrics.
(3)
Each PSU converts into Common Shares on a one-for-one basis.
(4)
This number represents Common Shares withheld to satisfy the tax withholding obligations due upon vesting of PSUs.
(5)
This PSU award was previously reported on a Form 3 filed on August 10, 2018 with the target award amount of 5,461 shares. Any portion of the award not vested on February 19, 2020 was cancelled as of that date.
2/26/20
+13,506 @ $0
2/28/20
-2,499 shares @ $24.44 = $61,075.56
3/9/20
-2,239 Shares @ $20.96 = $46,929.44
Fat Joe’s protégé, Joe (little) Gordon, sold 18,559 shares in Q1 2020 averaging approximately $25.92/share totaling $480,977.94. Not bad, but nothing compared to Fat Joe!
Does little Joe know who the Bear Jew is?
“We are pleased with the findings of the court, which demonstrates the integrity of our PreserVision AREDS and AREDS 2 Formula eye vitamins to meet the needs of eye care professionals and their patients,” Joseph Gordon, senior vice president and general manager, Bausch + Lomb Consumer Healthcare, said in the news release. “As the leader in ocular nutrition, Bausch + Lomb is committed to providing the most current, science-based eye vitamin formulations. Therefore, when these or any of our products are infringed, we will vigorously defend our intellectual property and innovations to ensure our customers can continue to rely on products that are based on a robust body of scientific and clinical research.”
Little Joe is not, nor is B+L, the leader in anything other than being a weak and deceptive fraud.